Most studies looking at THA in hemophilia patients do not have AVN as the indication for THA and focus on management and outcomes of hemophilia A patients with no commentary on patients with hemophilia B. While rates of total joint replacement have been shown to be the same in patients with hemophilia A and B, hemophilia B has a much lower incidence rate, and guidelines have established that factor IX has a longer half-life at 18-34 hours than factor VIII (8-12 hours), necessitating different management strategies perioperatively for these patients [7,12,13]. The gene discussed is F9; the disease is hemophilia B.